title: Recombinant factor VIIa in trauma patients without coagulation disorders.
abstract: Recombinant activated factor VIIa (rFVIIa) has many clinical applications for patients with congenital bleeding disorders and in a variety of clinical settings. Additional studies in the future are ongoing and should provide the clinical anesthesiologist an additional option during certain bleeding states. Specific recommendations as to timing of administration and frequent monitoring of ionized calcium status are suggested at this time. Optimization of fibrinogen levels, platelet levels, pH, and body temperature will enhance efficacy of rFVIIa.
authors.affiliation: Department of Anesthesiology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467-2490, USA. coreyscher@gmail.com
authors.forename: Corey
authors.initials: C
authors.lastname: Scher
authors.forename: Venod
authors.initials: V
authors.lastname: Narine
authors.forename: Daniel
authors.initials: D
authors.lastname: Chien
mesh_terms: D002543:Cerebral Hemorrhage / Q000188:drug therapy; D015942:Factor VIIa / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy; D002836:Hemophilia B / Q000188:drug therapy; D006801:Humans; D006473:Postpartum Hemorrhage / Q000188:drug therapy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D013925:Thromboplastin / Q000502:physiology; D014857:Warfare; D014947:Wounds and Injuries / Q000150:complications / Q000188:drug therapy*
chemical_list: D011994:Recombinant Proteins; D013925:Thromboplastin; C103587:recombinant FVIIa; D015942:Factor VIIa